Literature DB >> 16948524

Are gadolinium-based contrast media nephrotoxic? A renal biopsy study.

Hulya Akgun1, Gulfiliz Gonlusen, Joiner Cartwright, Wadi N Suki, Luan D Truong.   

Abstract

Gadolinium-based contrast media were originally introduced as alternatives to iodinated media for magnetic resonance imaging. Although originally thought to be nonnephrotoxic, gadolinium-based contrast media have recently been reported to be associated with acute renal failure; the mechanism and the underlying renal injury are not completely understood. We report what is, to our knowledge, the first renal biopsy in this context. A 56-year-old patient underwent 2 consecutive vascular imaging procedures in conjunction with gadolinium-based contrast medium administration. A few days later, the patient developed acute renal failure. A renal biopsy showed acute tubular cell injury including patchy tubular cell necrosis, tubular cell degeneration, and marked proliferation of tubular cells, together with mild interstitial edema and interstitial inflammation, but without significant glomerular or vascular changes. During supportive therapy, renal function was partially regained. This case emphasizes the potential nephrotoxicity of gadolinium-based contrast media and suggests that the nephrotoxicity is related to potentially reversible acute tubular cell injury.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16948524     DOI: 10.5858/2006-130-1354-AGCMNA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  19 in total

1.  Biocompatible iron(II)-doped carbon dots as T1-weighted magnetic resonance contrast agents and fluorescence imaging probes.

Authors:  Qing Huang; Yue Liu; Linling Zheng; Liping Wu; Zhengyu Zhou; Jiafei Chen; Wei Chen; Huawen Zhao
Journal:  Mikrochim Acta       Date:  2019-07-02       Impact factor: 5.833

Review 2.  Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines.

Authors:  Fulvio Stacul; Aart J van der Molen; Peter Reimer; Judith A W Webb; Henrik S Thomsen; Sameh K Morcos; Torsten Almén; Peter Aspelin; Marie-France Bellin; Olivier Clement; Gertraud Heinz-Peer
Journal:  Eur Radiol       Date:  2011-08-25       Impact factor: 5.315

3.  Dotted Core-Shell Nanoparticles for T1 -Weighted MRI of Tumors.

Authors:  Zheyu Shen; Jibin Song; Zijian Zhou; Bryant C Yung; Maria A Aronova; Yan Li; Yunlu Dai; Wenpei Fan; Yijing Liu; Zihou Li; Huimin Ruan; Richard D Leapman; Lisen Lin; Gang Niu; Xiaoyuan Chen; Aiguo Wu
Journal:  Adv Mater       Date:  2018-07-04       Impact factor: 30.849

4.  Gadolinium-based contrast agents: Stimulators of myeloid-induced renal fibrosis and major metabolic disruptors.

Authors:  Catherine Do; Bridget Ford; Doug Yoon Lee; Chunyan Tan; Patricia Escobar; Brent Wagner
Journal:  Toxicol Appl Pharmacol       Date:  2019-05-10       Impact factor: 4.219

Review 5.  Effects of nanomaterial physicochemical properties on in vivo toxicity.

Authors:  Kristin L Aillon; Yumei Xie; Nashwa El-Gendy; Cory J Berkland; M Laird Forrest
Journal:  Adv Drug Deliv Rev       Date:  2009-04-20       Impact factor: 15.470

6.  Assessment of Gadobutrol Safety in Combination with Ionizing Radiation Using a Preclinical MRI-Guided Radiotherapy Model.

Authors:  Michael S Petronek; Emily J Steinbach; Amanda L Kalen; Zachariah J Builta; Cameron M Callaghan; Dan E Hyer; Douglas R Spitz; Ryan T Flynn; John M Buatti; Vincent A Magnotta; Diana Zepeda-Orozco; Joël J St-Aubin; Bryan G Allen
Journal:  Radiat Res       Date:  2021-03-01       Impact factor: 2.841

7.  Gadolinium distribution in kidney tissue determined and quantified by micro synchrotron X-ray fluorescence.

Authors:  Wolf Osterode; Gerald Falkenberg; Heinz Regele
Journal:  Biometals       Date:  2021-01-23       Impact factor: 2.949

8.  Gadolinium-based contrast media exposure and the possible risk of subclinical kidney damage: a pilot study.

Authors:  Francesca Martino; Gianpaolo Amici; Ilaria Godi; Michele Baretta; Caterina Biasi; Mariarosa Carta; Valentina Corradi; Massimo De Cal; MaÍra Knust; Claudia Tamayod; Alessia Varotto; Giuseppe Iannucci; Davide Giavarina; Sergio Savastano; Claudio Ronco
Journal:  Int Urol Nephrol       Date:  2021-01-13       Impact factor: 2.370

9.  Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study).

Authors:  Gilbert Deray; Olivier Rouviere; Lorenzo Bacigalupo; Bart Maes; Thierry Hannedouche; François Vrtovsnik; Claire Rigothier; Jean-Marie Billiouw; Paolo Campioni; Joaquin Ferreiros; Daniel Devos; Daniel Alison; François Glowacki; Jean-Jacques Boffa; Luis Marti-Bonmati
Journal:  Eur Radiol       Date:  2012-12-05       Impact factor: 5.315

Review 10.  Quantitative evaluation of muscle perfusion with CEUS and with MR.

Authors:  Marc-André Weber; Martin Krix; Stefan Delorme
Journal:  Eur Radiol       Date:  2007-04-24       Impact factor: 7.034

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.